Praxis Precision Medicines (PRAX) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$2.87

Estimate

-$3.69

Surprise

+22.2%

Score today

5.7/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Praxis Precision Medicines (PRAX) reported a narrower loss than forecast — diluted EPS of -$2.87 against the -$3.69 estimate (a 22.2% beat on a still-unprofitable quarter).

TrendMatrix currently rates PRAX Sell at 5.7/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +22.2% surprise compares with a +6.7% four-quarter average. Next scheduled report: 2026-11-09.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$350.61

Price target

$574.82

Stop

$326.07

Upside to target

+63.9%

Reward-to-risk

6.3:1

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$9.92B

P/E (fwd)

-38.2

52-week range

$37.19–$392.70

Off 52-week high

10.7%

RSI (14)

40

Volume vs avg

0.24×

Score today

5.7/10